Disclosures: Hee Sun Cho: Nothing to Disclose, Jaejun Lee: Nothing to Disclose, Ah Lim Lee: Nothing to Disclose, Hyun Yang: Nothing to Disclose 1111 A PROSPECTIVE ASSESSMENT OF THE IMPACT OF DECOMPENSATION OF CIRRHOSIS ON PATIENT-REPORTED OUTCOMES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Ian O'Connor 1 Andrea Mospan 2 Cheryl Schoen 2 Alfred Barritt IV 3 Arun Sanyal 1 , 1 Virginia Commonwealth University, 2 Target RWE, 3 University of North Carolina Background: Metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD and MASH) are major causes of liver-related morbidity and mortality
Notably, semaglutide treatment did not affect the plasma concentrations of these metabolic hormones in healthy WT mice (Figure 6, BL)
This group is known as a class. The class represents the interests of a larger group of people with similar injuries and claims
I want to close by tying these threads back to the learning outcomes and the core message I carry into every pharmacology course I teach
You know, they, this is, Eli Lilly is going to be worth more than any pharmaceutical company in the world
